A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

Siddhartha Devarakonda, Bruna Pellini, Luke Verghese, Haeseong Park, Daniel Morgensztern, Ramaswamy Govindan, Rama Suresh, Peter Oppelt, Maria Q. Baggstrom, Ningying Wu, Saiama N. Waqar